ImmuneBiotech and Lund University Launch a Pioneering Clinical Study Linking Gut Health to Preeclampsia Prevention

Lund, Sweden – ImmuneBiotech, a pioneering innovator in probiotic solutions, today announced a collaborative clinical study with researchers from Lund University and Region Skåne. The study aims to investigate whether restoring gut health through probiotics can help lower the risk of preeclampsia, a severe pregnancy complication affecting millions of women worldwide.

Preeclampsia, often referred to as pregnancy-induced hypertension, is one of the leading causes of maternal and fetal mortality globally. Marked by high blood pressure and associated complications, it can occur suddenly in seemingly healthy pregnancies, frequently requiring early delivery. Alarmingly, hypertensive disorders during pregnancy account for over 76,000 maternal deaths annually across the globe.

“Current treatment options for preeclampsia are very limited,” explains Professor Stefan Hansson of Lund University and Skåne University Hospital, the principal investigator of the study. “This clinical study offers the possibility of groundbreaking preventative strategies that could significantly improve care for expectant mothers worldwide.”

Recent research has highlighted the critical role of gut flora in overall health, with emerging evidence linking gut dysbiosis, inflammation, and intestinal barrier dysfunction to preeclampsia. A 2023 study*, conducted collaboratively by Professor Stefan Hansson’s research team and ImmuneBiotech, confirmed these connections, showing that pregnant women in Sweden with preeclampsia exhibited a significant imbalance in their gut microbiome compared to healthy pregnancies and frequently reported gut-related symptoms.

* Read more at PubMed

Building on these findings, the new clinical trial, registered on ClinicalTrials.gov**, will explore whether restoring gut microbiome balance, strengthening the intestinal barrier, and suppressing inflammation through GutMagnific® - ImmuneBiotech’s scientifically designed probiotic blend - can help reduce the risk of this life-threatening condition. The study will include 150 pregnant women with risk, who will receive either GutMagnific® or a placebo, with researchers monitoring microbiomes, inflammation markers, and pregnancy outcomes.

** Study Details at ClinicalTrials.gov

GutMagnific® contains five carefully selected strains of lactic acid bacteria, chosen for their ability to restore gut balance and reduce systemic inflammation, offering an innovative and natural approach to preeclampsia prevention. This research represents a significant step toward improving maternal health outcomes through precision probiotics.

“Gut health is increasingly recognized as a cornerstone of overall well-being,” says Dr. Shahram Lavasani, CEO of ImmuneBiotech. “We are excited to investigate the potential of GutMagnific® as a preventative solution for preeclampsia, providing expectant mothers with a safe, natural, and scientifically grounded approach to supporting a healthy pregnancy.”


Read the full press release

For more information, please contact:
Shahram Lavasani, CEO
ImmuneBiotech Medical Sweden AB
s.lavasani@immunebiotech.com
+46 700 90 8946
www.ImmuneBiotech.com

 

---

---